156 related articles for article (PubMed ID: 27362841)
21. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
Wimmer NJ; Dufour AB; Cho K; Gagnon DR; Quach L; Ly S; Do JM; Ostrowski S; Michael Gaziano J; Faxon DP; Kinlay S
Catheter Cardiovasc Interv; 2017 Jun; 89(7):1176-1184. PubMed ID: 27860195
[TBL] [Abstract][Full Text] [Related]
22. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
[TBL] [Abstract][Full Text] [Related]
23. Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement.
Shah RR; Pillai A; Omar A; Zhao J; Arora V; Kapoor D; Poommipanit P
Catheter Cardiovasc Interv; 2017 Mar; 89(4):E99-E103. PubMed ID: 27184930
[TBL] [Abstract][Full Text] [Related]
24. Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease.
Krackhardt F; Waliszewski M; Kočka V; Toušek P; Janek B; Hudec M; Lozano F; Roman KG; Del Blanco BG; Mauri J; Heang TM; Ahn TH; Jeong MH; Herberger D; Tomulic V; Levy G; Sebagh L; Rischner J; Pansieri M
Cardiovasc Drugs Ther; 2020 Jun; 34(3):335-344. PubMed ID: 32212061
[TBL] [Abstract][Full Text] [Related]
25. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
[TBL] [Abstract][Full Text] [Related]
26. Clinical Outcomes in Patients Treated With Biodegradable-Polymer Biolimus-Eluting Stents and 6 Months of Dual-Antiplatelet Therapy: The French eBiomatrix 6-Month DAPT Registry.
Lipiecki J; Rampat R; Piot C; Benamer H; Brunelle F; Lefèvre T; El Mahmoud R; Varenne O; Gommeaux A; Malquarti V; Angoulvant D; Cruchon C; Oldroyd K; Spaulding C
J Invasive Cardiol; 2022 May; 34(5):E363-E368. PubMed ID: 35451995
[TBL] [Abstract][Full Text] [Related]
27. Consideration of dual anti-platelet therapy duration after drug-eluting stent implantation in a Japanese population: a five-year follow-up after sirolimus-eluting stent implantation.
Kotani J; Ikari Y; Kyo E; Nakamura M; Yokoi H;
Intern Med; 2013; 52(7):703-11. PubMed ID: 23545663
[TBL] [Abstract][Full Text] [Related]
28. One-year clinical outcomes between biodegradable-polymer-coated biolimus-eluting stent and durable-polymer-coated drug-eluting stents in STEMI patients with multivessel coronary artery disease undergoing culprit-only or multivessel PCI.
Kim YH; Her AY; Jeong MH; Kim BK; Lee SY; Hong SJ; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Atherosclerosis; 2019 May; 284():102-109. PubMed ID: 30877937
[TBL] [Abstract][Full Text] [Related]
29. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.
Yeh RW; Kereiakes DJ; Steg PG; Cutlip DE; Croce KJ; Massaro JM; Mauri L;
J Am Coll Cardiol; 2017 Oct; 70(18):2213-2223. PubMed ID: 29073947
[TBL] [Abstract][Full Text] [Related]
30. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
[TBL] [Abstract][Full Text] [Related]
31. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
32. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
[TBL] [Abstract][Full Text] [Related]
33. An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary Intervention.
Yamamoto K; Natsuaki M; Watanabe H; Morimoto T; Obayashi Y; Nishikawa R; Ando K; Suwa S; Isawa T; Takenaka H; Ishikawa T; Tamura T; Kawahatsu K; Hayashi F; Akao M; Serikawa T; Mori H; Kawamura T; Hagikura A; Shibata N; Ono K; Kimura T;
JACC Cardiovasc Interv; 2024 May; 17(9):1119-1130. PubMed ID: 38749592
[TBL] [Abstract][Full Text] [Related]
34. Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
Zuliani Mauro MF; Mangione JA; Costa JR; Costa R; Piva E Mattos LA; Staico R; Feres F; Siqueira D; Sousa A; Abizaid A
J Invasive Cardiol; 2017 Mar; 29(3):76-81. PubMed ID: 28255102
[TBL] [Abstract][Full Text] [Related]
35. Comparison of outcomes in patients with or without ARC-HBR criteria undergoing PCI with polymer-free biolimus coated stents: The BioFreedom France study.
Garot P; Brunel P; Dibie A; Morelle JF; Abdellaoui M; Levy R; Carrié D; Karsenty B; Robin C; Berland J; Copt S; Sadozai Slama S; Oldroyd K; Morice MC; Lipiecki J;
Catheter Cardiovasc Interv; 2023 Jan; 101(1):60-71. PubMed ID: 36378683
[TBL] [Abstract][Full Text] [Related]
36. Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
Valgimigli M; Cao D; Angiolillo DJ; Bangalore S; Bhatt DL; Ge J; Hermiller J; Makkar RR; Neumann FJ; Saito S; Picon H; Toelg R; Maksoud A; Chehab BM; Choi JW; Campo G; De la Torre Hernandez JM; Kunadian V; Sardella G; Thiele H; Varenne O; Vranckx P; Windecker S; Zhou Y; Krucoff MW; Ruster K; Zheng Y; Mehran R;
J Am Coll Cardiol; 2021 Nov; 78(21):2060-2072. PubMed ID: 34794687
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Palmerini T; Stone GW
Clin Res Cardiol; 2017 Mar; 106(3):165-173. PubMed ID: 27631821
[TBL] [Abstract][Full Text] [Related]
38. Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
Song YB; Oh SK; Oh JH; Im ES; Cho DK; Cho BR; Lee JY; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; Hahn JY
Am Heart J; 2018 Mar; 197():77-84. PubMed ID: 29447787
[TBL] [Abstract][Full Text] [Related]
39. Predictors and variability of drug-eluting vs bare-metal stent selection in contemporary percutaneous coronary intervention: Insights from the PRISM study.
Shafiq A; Gosch K; Amin AP; Ting HH; Spertus JA; Salisbury AC
Clin Cardiol; 2017 Aug; 40(8):521-527. PubMed ID: 28300284
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of polymer-free biolimus-eluting stents versus ultrathin stents in unprotected left main or coronary bifurcation: A propensity score analysis from the RAIN and CHANCE registries.
D'Ascenzo F; Gaido L; Bernardi A; Saglietto A; Franzé A; Ielasi A; Trabattoni D; Di Biasi M; Infantino V; Rognoni A; Helft G; Gangor A; Latini RA; De Luca L; Mitomo S; Ugo F; Smolka G; Huczek Z; Cortese B; Capodanno D; Chieffo A; Piazza F; di Mario C; Poli A; D'Urbano M; Romeo F; Giammaria M; Varbella F; Sheiban I; Escaned J; De Ferrari GM
Catheter Cardiovasc Interv; 2020 Feb; 95(3):522-529. PubMed ID: 31385427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
